Toward a Faster, More Accurate Way to Diagnose Stroke
News Apr 10, 2014
When someone suffers from a stroke, a silent countdown begins. A fast diagnosis and treatment can mean the difference between life and death. So scientists are working on a new blood test that one day could rapidly confirm whether someone is having a stroke and what kind. Their report appears in the ACS journal Analytical Chemistry.
Steven A. Soper and colleagues note that strokes, which are the third leading cause of death and disability in the United States, have two possible causes. In ischemic strokes, a clot stops blood flow in a part of the brain. In hemorrhagic stroke, a blood vessel in the brain ruptures. Both can lead to similar symptoms, such as numbness on one side of the body, sudden weakness and headache. Current diagnostic tests can’t tell between these two types. But treatment, ideally within three hours of onset, depends on the kind of stroke a person is having. Soper’s collaborator, Alison Baird, who is at SUNY Downstate Stroke Center, found clues — or biomarkers — in the blood that can suggest the stroke type and assist in determining the course of proper treatment. Soper’s team sought a way to detect those clues quickly.
They built a device that can process whole blood and isolate genetic material for two potential stroke biomarkers within minutes. Keeping in mind that identifying more biomarkers could aid in diagnosis, they designed their device so it can analyze a total of four biomarkers at the same time.
The article is entitled "Parallel Affinity-Based Isolation of Leukocyte Subsets Using Microfluidics: Application for Stroke Diagnosis" .
All in a Droplet: Atomic Resolution of ALS Protein ResolvedNews
Researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases of muscle and bone.READ MORE
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE